mercredi 4 avril 2018

Onco Actu du 4 avril 2018

1. Biologie

Answers to 100-year-old mystery point to potential breast cancer therapies [Baylor College of Medicine]

New TCGA Papers Shed Light on Cancer Development [Genome Web]

2.11 Etiologie - Alimentation

Coffee and Cancer: What the Research Really Shows [ACS]

3.7 Prévention - Alcool

NIH Turned Down Investigators Who Provoked Ire From Alcohol Industry [The Scientist]

4. Dépistage, diagnostic et pronostic

One centre for cancer diagnoses trialled [Pharmafile]

4.12 Biopsies liquides

Liquid biopsy of cerebrospinal fluid for the precise characterization and molecular diagnosis of brain tumors [VHIO]

'This is like finding a needle in a haystack': U of T researchers develop liquid biopsy technology for prostate cancer [University of Toronto]

4.2 Dép., diag. & prono. - Génome

Home Genetic Tests May Be Riddled With Errors, And Companies Aren’t Keeping Track [HuffPost]

5.1 Traitements - Pré-clinique

Study reveals a way to make prostate cancer cells run out of energy and die [CSHL]

Lung cancer drug shows promise as targeted therapy for thousands with breast cancer [Institute of Cancer Research]

DNA-encoded molecules provide a new edge in cancer drug hunts [Novartis]

5.10 Traitements - Essais

Cancer researchers push to relax rules for clinical trials [Nature]

5.12 Immunothérapies

Penn Study Maps Potential of Manipulating Gut Microbiome to Boost Efficacy of Cancer Immunotherapies [Penn Medicine]

5.12.2 Immunothérapies - CAR-T

Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies [Cellectis]

Ex-Kite Execs Resurface with $300M and Control of Pfizer CAR-T Cells [Xconomy]

Pfizer in deal with Allogene to develop cancer cell therapies [Reuters]

They built a game-changing cancer-killing therapy. Now they’re taking on a new kind of CAR-T therapy [STAT]

Pfizer and Allogene Therapeutics Enter Into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio [Allogene]

Arie Belldegrun raises $300M, grabs Pfizer’s allogeneic CAR-T portfolio and launches a groundbreaking drive to commercialization [EndPoints]

They're Back! After Selling Kite, Belldegrun And Chang Seek To Change Cancer Treatment Again [Forbes]

5.2 Pharma

AstraZeneca leukemia drug bags priority review status, setting up third-quarter approval [FierceBiotech]

High-flying biotech Loxo tempers bullish view for cancer drug [Reuters]

5.2.3 Pharma - économie

The top 15 drug patent expirations of 2018 [FiercePharma]

6. Lutte contre les cancers

UK's first proton beam cancer centre to open in Newport [BBC News]

6.1 Observation

For women with kidney cancer, belly fat matters [WUSTL]

6.4 Médico-éco

Can Doctors Choose Between Saving Lives and Saving a Fortune? [NY Times]

6.6 Publications

A Reality Check on Author Access to Open Access Publishing [Absolutely Maybe]

6.7.1 IA/bioinformatique

UK can be ‘world leader in AI’ if NHS data can be tapped [Digital Health]